These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2683263)

  • 21. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
    Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
    Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of delayed graft function in cyclosporine-treated recipients of cadaver kidney transplants.
    Barry JM; Shively N; Hubert B; Hefty T; Norman DJ; Bennett WM
    Transplantation; 1988 Feb; 45(2):346-8. PubMed ID: 3278427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine.
    Hall BM; Tiller DJ; Duggin GG; Horvath JS; Farnsworth A; May J; Johnson JR; Sheil AG
    Kidney Int; 1985 Aug; 28(2):178-86. PubMed ID: 3914572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The quality of initial function following renal transplantation determined by creatinine elimination kinetics. Comparison of Minnesota antilymphocyte globulin and cyclosporine induction immunosuppression.
    Shackleton CR; Keown PA; McLoughlin MG; Scudamore CH; Schechter MT; Cameron EC; Yeung CK; Kane LM; Manson AD; Landsberg DN
    Transplantation; 1991 Dec; 52(6):1008-13. PubMed ID: 1750062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients.
    Kasiske BL; Johnson HJ; Goerdt PJ; Heim-Duthoy KL; Rao VK; Dahl DC; Ney AL; Andersen RC; Jacobs DM; Odland MD
    Am J Kidney Dis; 1997 Nov; 30(5):639-45. PubMed ID: 9370178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative antirejection treatment with steroids or antilymphoblast globulin in renal transplant patients receiving cyclosporine.
    Veremis SA; Maddux MS; Pollak R; Kline SS; Mozes MF
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1893-5. PubMed ID: 3079056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation.
    Taylor HE; Ackman CF; Horowitz I
    Can Med Assoc J; 1976 Dec; 115(12):1205-8. PubMed ID: 793705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation.
    Kupin WL; Venkatachalam KK; Oh HK; Dienst S; Levin NW
    Transplantation; 1985 Dec; 40(6):601-4. PubMed ID: 3907029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function.
    Kaufman DB; Morel P; Condie R; Field MJ; Rooney M; Tzardis P; Stock P; Sutherland DE
    Transplantation; 1991 Jan; 51(1):37-42. PubMed ID: 1987703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peri-operative antilymphoblast globulin (ALG) and delayed initiation of cyclosporine (CsA) diminishes the requirement for prolonged dialysis therapy after renal transplantation.
    Nestor ZJ; Rocher LL; Merion RM; Swartz RD; Turcotte JG; Campbell DA
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1556-7. PubMed ID: 2652505
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF.
    Ding C; Xue W; Tian P; Ding X; Pan X; Yan H; Xiang H; Feng X; Hou J; Tian X; Li Y; Zheng J
    Int J Clin Pract Suppl; 2015 May; (183):8-15. PubMed ID: 26176940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Najarian JS; Fryd DS; Strand M; Canafax DM; Ascher NL; Payne WD; Simmons RL; Sutherland DE
    Ann Surg; 1985 Feb; 201(2):142-57. PubMed ID: 3882063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction immunosuppressive therapy stratified according to risk categories in renal transplantation.
    Troncoso P; Ortiz AM; Jara A
    Transplant Proc; 2003 Nov; 35(7):2495-9. PubMed ID: 14611995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.